Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Amneal Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 39.3%. For fiscal 2025 it was 36.9%, against 36.5% the year before. The highest annual figure on record is 58.7% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36.9% | +0.4 |
| FY2024 | Dec 31, 2024 | 36.5% | +2.2 |
| FY2023 | Dec 31, 2023 | 34.3% | −1.2 |
| FY2022 | Dec 31, 2022 | 35.5% | −1.3 |
| FY2021 | Dec 31, 2021 | 36.7% | +5.2 |
| FY2020 | Dec 31, 2020 | 31.5% | +9.8 |
| FY2019 | Dec 31, 2019 | 21.7% | −21.4 |
| FY2018 | Dec 31, 2018 | 43.1% | −7.8 |
| FY2017 | Dec 31, 2017 | 50.9% | −7.8 |
| FY2016 | Dec 31, 2016 | 58.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 42.0% | +2.5 |
| Q1 FY2026 | Mar 31, 2026 | 44.3% | +7.5 |
| Q4 FY2025 | Dec 31, 2025 | 36.5% | +0.5 |
| Q3 FY2025 | Sep 30, 2025 | 34.9% | −3.5 |
| Q2 FY2025 | Jun 30, 2025 | 39.5% | +3.9 |
| Q1 FY2025 | Mar 31, 2025 | 36.8% | +0.7 |
| Q4 FY2024 | Dec 31, 2024 | 36.0% | +5.2 |
| Q3 FY2024 | Sep 30, 2024 | 38.4% | +0.9 |
| Q2 FY2024 | Jun 30, 2024 | 35.6% | −1.1 |
| Q1 FY2024 | Mar 31, 2024 | 36.1% | +4.2 |
| Q4 FY2023 | Dec 31, 2023 | 30.8% | −4.6 |
| Q3 FY2023 | Sep 30, 2023 | 37.5% | +1.9 |
| Q2 FY2023 | Jun 30, 2023 | 36.7% | +0.9 |
| Q1 FY2023 | Mar 31, 2023 | 32.0% | −3.1 |
| Q4 FY2022 | Dec 31, 2022 | 35.3% | +4.3 |
| Q3 FY2022 | Sep 30, 2022 | 35.6% | −2.0 |
| Q2 FY2022 | Jun 30, 2022 | 35.8% | −3.9 |
| Q1 FY2022 | Mar 31, 2022 | 35.1% | −3.8 |
| Q4 FY2021 | Dec 31, 2021 | 31.0% | −1.8 |
| Q3 FY2021 | Sep 30, 2021 | 37.6% | +11.8 |
| Q2 FY2021 | Jun 30, 2021 | 39.7% | +8.7 |
| Q1 FY2021 | Mar 31, 2021 | 38.8% | +2.0 |
| Q4 FY2020 | Dec 31, 2020 | 32.8% | +5.0 |
| Q3 FY2020 | Sep 30, 2020 | 25.7% | +11.3 |
| Q2 FY2020 | Jun 30, 2020 | 31.0% | +5.0 |
| Q1 FY2020 | Mar 31, 2020 | 36.8% | +18.2 |
| Q4 FY2019 | Dec 31, 2019 | 27.7% | −11.1 |
| Q3 FY2019 | Sep 30, 2019 | 14.4% | −27.6 |
| Q2 FY2019 | Jun 30, 2019 | 26.0% | −17.1 |
| Q1 FY2019 | Mar 31, 2019 | 18.6% | −33.9 |
| Q4 FY2018 | Dec 31, 2018 | 38.9% | −12.7 |
| Q3 FY2018 | Sep 30, 2018 | 42.0% | −11.0 |
| Q2 FY2018 | Jun 30, 2018 | 43.1% | −4.5 |
| Q1 FY2018 | Mar 31, 2018 | 52.5% | +1.1 |
| Q4 FY2017 | Dec 31, 2017 | 51.6% | – |
| Q3 FY2017 | Sep 30, 2017 | 53.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 47.6% | – |
| Q1 FY2017 | Mar 31, 2017 | 51.4% | – |
See a number that looks wrong?